Phase II Trial of Erlotinib and Docetaxel in Advanced and Refractory Hepatocellular and Biliary Cancers: Hoosier Oncology Group GI06-101

BACKGROUND: Patients with advanced hepatocellular (HCC) and biliary tract carcinomas (BTC) have poor prognosis. While the EGFR pathway is overactive in HCC and BTC, single agent anti-EGFR therapies confer modest activity. Preclinical data showed synergistic antiproliferative and proapoptotic effects...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Chiorean, E. Gabriela, Ramasubbaiah, Rashmi, Yu, Menggang, Picus, Joel, Bufill, Jose A., Tong, Yan, Coleman, Nicki, Johnston, Erica L., Currie, Colleen, Loehrer, Patrick J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: AlphaMed Press 2012
Soggetti:
Clinical Trial Reports
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3267812/
https://ncbi.nlm.nih.gov/pubmed/22210086
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0253
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi